Rafael Rosell

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin, and a multibiomarker profile predictive of patient outcome is refined.

TL;DR: Identification of the molecular components involved could lead to the development of combination therapies cotargeting these molecules instead of EGFR tyrosine kinase inhibitor monotherapy, and novel biomarkers could be identified through deep sequencing analysis of serial rebiopsies before and during treatment.

TL;DR: This review adds to a growing body of knowledge into mechanisms of resistance that can be interrogated in NSCLC patients with EGFR mutations or EML4-ALK fusions, as well as strategies to overcome resistance to TKIs.

TL;DR: This data indicates that low-frequency lesions that affect a druggable gene product allow a relatively small population of cancer patients for targeted therapy to be selected.